Free Newsletter
Frank Torti, future FDA chief?
From scientist-in-chief to top chief? Frank Torti, a cancer researcher who joined FDA two months ago, may be in line for the commissioner's job. Beltway wags say the current leader, Andrew von Eschenbach, is likely on his way out after the presidential election in November--no matter who wins. Torti could have the inside track: As scientist in chief, he'd be a logical choice for interim commissioner. And that's how von Eschenbach ended up in the job. Torti's only comment was noncommittal. “I’m not in the habit of taking a job no one’s told me about yet," he told the Pink Sheet. For a peek at his current policy plans, see the RPM Report's link.
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: